Literature DB >> 22791775

Pretransplant MRD: the light is yellow, not red.

Alan S Wayne1, Jerald P Radich.   

Abstract

In the study reported in this issue of Blood by Leung et al, detectable minimal residual disease (MRD) before hematopoietic stem cell transplantation (HSCT) was found to be prognostic for outcome, but did not prevent cure for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

Entities:  

Year:  2012        PMID： 22791775     DOI： 10.1182/blood-2012-05-427443

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  4 in total

1.  A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD).

Authors:  N Gossai; M R Verneris; N A Karras; M F Gorman; N J Patel; M J Burke
Journal:  Bone Marrow Transplant       Date:  2013-12-09       Impact factor: 5.483

Review 2.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675

Review 3.  New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.

Authors:  M A Pulsipher; A S Wayne; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2014-06-16       Impact factor: 5.483

4.  Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.

Authors:  Nirali N Shah; Michael J Borowitz; Seth M Steinberg; Nancy C Robey; Christopher J Gamper; Heather J Symons; David M Loeb; Alan S Wayne; Allen R Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-30       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.